Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards

Who is this study for? Patients with Hypomagnesemia
What treatments are being studied? Magnesium Citrate
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

Hypomagnesemia is a common entity in the inpatient and outpatient setting. in previous retrospective study hypomagnesemic patients have higher mortality and longer hospitalization. whether hypomagnesemia is merely a marker of poor prognosis, or whether replacing it can improve outcomes is unclear. The current standard of care is to discharge these patients without workup or further treatment, even if patients had received intravenous therapy while hospitalized. The investigator wish to examine prospectively whether giving replacement therapy affects mortality, length of hospital stay and overall well-being. In order to replete intracellular levels and replete magnesium stores, magnesium should be given for several months.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:

• Any patient admitted over the age of 18, has hypomagnesemia (magnesium level ≤1.9 mg/dL) and is able to give consent.

Locations
Other Locations
Israel
Emek Medical Center
RECRUITING
Afula
Contact Information
Primary
Frieda Wolf
friedawo@clalit.org.il
972-4-6495476
Backup
Rotem Shvartzman
rotem_sw@clait.org.il
972-4-6495351
Time Frame
Start Date: 2017-05-10
Estimated Completion Date: 2026-12
Participants
Target number of participants: 330
Treatments
Active_comparator: Experimental group
After initial intravenous treatment, participants (those with magnesium level ≥1 mg/dL) will be randomized, and oral magnesium therapy ( or no treatment) will be started. The experimental group will receive 400mg magnesium daily in two divided doses. Patients in the experimental group will be discharged with one month's supply of magnesium and continued for at least three months.
No_intervention: Control group
control group will receive standard care (no treatment). Patient will have their blood tested and will come for follow up visit every month for 3 months after discharge.
Related Therapeutic Areas
Sponsors
Leads: Frieda Wolf

This content was sourced from clinicaltrials.gov